Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.
D'Amico R, Yang Y, Mildvan D, Evans SR, Schnizlein-Bick CT, Hafner R, Webb N, Basar M, Zackin R, Jacobson MA. D'Amico R, et al. Among authors: schnizlein bick ct. J Clin Immunol. 2005 Mar;25(2):106-15. doi: 10.1007/s10875-005-2816-0. J Clin Immunol. 2005. PMID: 15821887 Clinical Trial.
Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy.
Goldman M, Zackin R, Fichtenbaum CJ, Skiest DJ, Koletar SL, Hafner R, Wheat LJ, Nyangweso PM, Yiannoutsos CT, Schnizlein-Bick CT, Owens S, Aberg JA; AIDS Clinical Trials Group A5038 Study Group. Goldman M, et al. Among authors: schnizlein bick ct. Clin Infect Dis. 2004 May 15;38(10):1485-9. doi: 10.1086/420749. Epub 2004 Apr 28. Clin Infect Dis. 2004. PMID: 15156489
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.
Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chêne G, D'Arminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JA, Saag MS; AIDS Clinical Trial Group DACS 241 Team; AIDS Clinical Trial Group Study 5095 Team; AIDS Clinical Trial Group Study 5142 team; Antiretroviral Cohort Collaboration. Mugavero MJ, et al. J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):253-60. doi: 10.1097/QAI.0b013e318230372e. J Acquir Immune Defic Syndr. 2011. PMID: 21857357 Free PMC article. Clinical Trial.
Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects.
Twigg Iii HL, Weiden M, Valentine F, Schnizlein-Bick CT, Bassett R, Zheng L, Wheat J, Day RB, Rominger H, Collman RG, Fox L, Brizz B, Dragavon J, Coombs RW, Bucy RP; AIDS Clinical Trials Group Protocol 723 Team. Twigg Iii HL, et al. Among authors: schnizlein bick ct. J Infect Dis. 2008 Jan 1;197(1):109-16. doi: 10.1086/523766. J Infect Dis. 2008. PMID: 18171293
36 results